Were Analysts Bullish ADMA Biologics Inc (NASDAQ:ADMA) This Week?

June 19, 2017 - By Vivian Currie

 Were Analysts Bullish ADMA Biologics Inc (NASDAQ:ADMA) This Week?
Investors sentiment decreased to 0.57 in Q4 2016. Its down 0.18, from 0.75 in 2016Q3. It is negative, as 0 investors sold ADMA Biologics Inc shares while 7 reduced holdings. 0 funds opened positions while 4 raised stakes. 7.94 million shares or 1.17% less from 8.03 million shares in 2016Q3 were reported.
Franklin Res Inc holds 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 359,499 shares. Weiss Multi accumulated 100,000 shares or 0.02% of the stock. Morgan Stanley accumulated 0% or 8,237 shares. Consonance Capital Management Limited Partnership holds 0.72% in ADMA Biologics Inc (NASDAQ:ADMA) or 1.27 million shares. Vanguard Group Inc, Pennsylvania-based fund reported 145,394 shares. 785 were accumulated by Tower Research Capital Limited Com (Trc). Bankshares Of America De reported 1 shares. Perceptive Advsr Limited Liability Co invested 0.26% in ADMA Biologics Inc (NASDAQ:ADMA). Broadfin Ltd has invested 0.63% in ADMA Biologics Inc (NASDAQ:ADMA). Aisling Ltd Liability Company reported 3.61 million shares. Blackrock Inv Ltd accumulated 856 shares or 0% of the stock. Fmr stated it has 423,100 shares. Geode Capital Mngmt Ltd Company accumulated 0% or 23,282 shares. 13,380 were reported by Spark Inv Mgmt Llc. Blackrock Fund Advisors holds 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 18,213 shares.

ADMA Biologics Inc (NASDAQ:ADMA) Ratings Coverage

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. ADMA Biologics had 5 analyst reports since September 9, 2015 according to SRatingsIntel. Maxim Group upgraded ADMA Biologics Inc (NASDAQ:ADMA) rating on Monday, January 23. Maxim Group has “Buy” rating and $13 target. The rating was downgraded by Raymond James to “Market Perform” on Monday, August 1. The rating was maintained by Maxim Group on Thursday, September 17 with “Buy”. The firm earned “Strong Buy” rating on Wednesday, September 9 by Raymond James. Maxim Group downgraded the stock to “Hold” rating in Monday, August 1 report. Below is a list of ADMA Biologics Inc (NASDAQ:ADMA) latest ratings and price target changes.

23/01/2017 Broker: Maxim Group Old Rating: Hold New Rating: Buy New Target: $13.00 Upgrade

It is down 37.56% since June 19, 2016 and is downtrending. It has underperformed by 54.26% the S&P500.

ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has market cap of $37.55 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.

More notable recent ADMA Biologics Inc (NASDAQ:ADMA) news were published by: Prnewswire.com which released: “Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of …” on March 27, 2017, also Seekingalpha.com with their article: “ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals” published on January 23, 2017, Globenewswire.com published: “ADMA Biologics Receives Complete Response Letter from FDA for Pending …” on July 29, 2016. More interesting news about ADMA Biologics Inc (NASDAQ:ADMA) were released by: Reuters.com and their article: “BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co’s …” published on June 16, 2017 as well as Globenewswire.com‘s news article titled: “ADMA Biologics to Present at Jefferies 2017 Healthcare Conference” with publication date: May 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.